This presentation summarizes ACT's business focusing on regenerative medicine technologies. It discusses ACT's multiple pluripotent stem cell platforms including single blastomere-derived embryonic stem cells and induced pluripotent stem cells. It provides details on ACT's clinical RPE program for treating dry AMD and Stargardt's disease, including preclinical research, manufacturing processes, clinical trial design and preliminary positive results from the first patients. It also outlines ACT's therapeutic pipeline including programs in retinal diseases, MSC technologies and combination product opportunities.